The trajectory of companies tied to Viagra's legacy presents a challenging investment scenario . While the initial success generated substantial gains, generic copies have significantly diminished revenue. Investing in related pharmaceutical firms now requires a careful assessment of patent safeguards, evolving medical trends , and the potential fo